Advertisement

ADVERTISEMENT

Jordan Kadish

News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
FDA Grants Approval to Polatuzumab Vedotin for Patients With Previously Untreated DLBCL and High-Grade B-Cell Lymphoma
04/21/2023
The FDA granted approval to polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) treatment for adult patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell...
The FDA granted approval to polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) treatment for adult patients with previously untreated DLBCL, not otherwise specified, or high-grade B-cell...
The FDA granted approval to...
04/21/2023
Oncology
News
Venetoclax, Azacitidine, and Homoharringtonine Regimen Well-Tolerated Among Patients With R/R AML
07/17/2023
The combination of venetoclax, azacitidine, and homoharringtonine was well-tolerated and demonstrated promising efficacy among patients with R/R acute myeloid leukemia.
The combination of venetoclax, azacitidine, and homoharringtonine was well-tolerated and demonstrated promising efficacy among patients with R/R acute myeloid leukemia.
The combination of venetoclax,...
07/17/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Chemo-Free Induction/Consolidation With Dasatinib and Blinatumomab Shows Long-Term Responses for Adult Patients With Philadelphia-Positive ALL
02/21/2024
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL
02/10/2023
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose...
02/10/2023
Oncology
News
PI3Kδ Inhibitor Linperlisib Clinical Activity Among Patients With R/R Follicular Lymphoma
03/28/2023
Oral PI3Kδ inhibitor linperlisib displayed compelling clinical activity and manageable tolerability among patients with R/R follicular lymphoma who had received 2 or more prior systemic therapies, according to a phase 2 trial.
Oral PI3Kδ inhibitor linperlisib displayed compelling clinical activity and manageable tolerability among patients with R/R follicular lymphoma who had received 2 or more prior systemic therapies, according to a phase 2 trial.
Oral PI3Kδ inhibitor linperlisib...
03/28/2023
Oncology
News
Romiplostim Treatment Shows Promise for Patients With Thrombocytopenia After Autologous Hematopoietic Cell Transplantation
08/09/2023
A pilot study indicated that romiplostim treatment enhanced platelet recovery to normal values after day 15 plus among patients with thrombocytopenia post-hematopoietic cell transplantation, but did not significantly shorten the duration and...
A pilot study indicated that romiplostim treatment enhanced platelet recovery to normal values after day 15 plus among patients with thrombocytopenia post-hematopoietic cell transplantation, but did not significantly shorten the duration and...
A pilot study indicated that...
08/09/2023
Oncology
News
Magrolimab and Azacitidine Combination Treatment for Patients With Untreated High-Risk MDS
04/28/2023
According to a phase 1b trial, magrolimab and azacitidine combination treatment yielded safe and effective results among patients with untreated high-risk myelodysplastic syndromes.
According to a phase 1b trial, magrolimab and azacitidine combination treatment yielded safe and effective results among patients with untreated high-risk myelodysplastic syndromes.
According to a phase 1b trial,...
04/28/2023
Oncology
News
Prognostic Value of PET Status for Patients With R/R Follicular Lymphoma Undergoing AutoSCT
07/31/2023
Pre-autologous stem cell transplantation positron emission tomography status has strong prognostic value and may help to improve the risk stratification and selection of patients for autoSCT, according to a retrospective analysis.
Pre-autologous stem cell transplantation positron emission tomography status has strong prognostic value and may help to improve the risk stratification and selection of patients for autoSCT, according to a retrospective analysis.
Pre-autologous stem cell...
07/31/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use